G
GeneBioHealth
A biotechnology company focusing on In Vitro Diagnostics (IVD) and human health
About GeneBioHealth
Based in Shenzhen, China, GeneBioHealth operates within the diagnostic equipment sector, focusing on the development and provision of medical diagnostic products and services. The company was founded in 2013 and has since established itself as a venture capital-backed entity in the life sciences and oncology verticals.
The firm's core business revolves around in-vitro diagnostic technology and molecular biology research. Its product and service portfolio includes diagnostic technology, reagents, and instruments. These offerings cater to several critical areas of medical diagnosis, including tumor diagnosis, human leukocyte antigen (HLA) typing, and point-of-care testing (POCT), enabling healthcare providers to diagnose major diseases at an early stage. A notable product developed in collaboration with a research team from the Chinese University of Hong Kong is the REColonTMmiR-92a Assay Kit, designed for the early screening of colorectal cancer. This product targets the miRNA-92a marker, selected for its stability, high detection sensitivity, and specificity in colon cancer.
GeneBioHealth's business model is centered on the research, development, and sale of these diagnostic solutions to users in the medical industry. The company is in a revenue-generating stage, supported by significant investment. A key financial milestone was a Series B1 funding round on October 18, 2020, which raised $15 million. This round was led by BOC Guangdong Finance and also included Fuho Capital, with the proceeds intended to fund the research and development of multiple pipeline products.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Oct 2022 | $15M | $60M | BOC Guangdong Finance | ↗ |
Growth signals
Latest recorded traffic for GeneBioHealth is 320 monthly website visits, down 62.4% over the last three months. GeneBioHealth's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
GeneBioHealth in the Shenzhen ecosystem
The GeneBioHealth office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
BOC Guangdong Finance
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about GeneBioHealth on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GeneBioHealth’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









